Gösswein T, Kocot A, Emmert G, Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Bork K, Oldenburg J, Müller C R
Department of Human Genetics, University of Wurzburg, Wurzburg, Germany.
Cytogenet Genome Res. 2008;121(3-4):181-8. doi: 10.1159/000138883. Epub 2008 Aug 28.
Hereditary angioedema (HAE) is an autosomal dominant disease that manifests as intermittent acute swellings of the skin and mucosal surfaces, which, in the gastrointestinal tract and larynx, may even be fatal. HAE results from functional deficiency of the C1 inhibitor (C1INH) protein, which plays a key role in the classical pathway of complement activation. C1INH is the sole inhibitor of the activated proteases C1r and C1s, and is the major regulator of activated coagulation Factor XII and plasma kallikrein, which limits the generation of the vasoactive peptide bradykinin. In this paper, we report on the genetic analysis of 173 families (including 326 members) with a clinical diagnosis of HAE. Direct sequencing, Southern blotting and quantitative PCR by the MLPA method were used to screen for mutations in C1INH (SERPING1). In 142 families (82.1%), a causative C1INH gene mutation could be identified. A total of 80 novel point mutations of C1INH not published previously were detected in 96 pedigrees (including 172 members). Our results corroborate C1INH (SERPING1) deficiency as a disease of extreme allelic heterogeneity with almost each individual family carrying their own mutation. Routine molecular genetic analysis is an effective way of confirming the clinical diagnosis and identifying mutation carriers early on before any clinical manifestation becomes apparent. It is, therefore, a valuable tool in prevention and adequate treatment of acute and life-threatening oedema.
遗传性血管性水肿(HAE)是一种常染色体显性疾病,表现为皮肤和黏膜表面间歇性急性肿胀,在胃肠道和喉部,这种肿胀甚至可能是致命的。HAE是由C1抑制剂(C1INH)蛋白功能缺陷引起的,该蛋白在补体激活的经典途径中起关键作用。C1INH是活化蛋白酶C1r和C1s的唯一抑制剂,也是活化凝血因子XII和血浆激肽释放酶的主要调节因子,可限制血管活性肽缓激肽的生成。在本文中,我们报告了对173个临床诊断为HAE的家族(包括326名成员)的基因分析。采用直接测序、Southern印迹和MLPA法进行定量PCR,以筛查C1INH(SERPING1)中的突变。在142个家族(82.1%)中,可鉴定出致病性C1INH基因突变。在96个家系(包括172名成员)中,共检测到80个先前未发表的C1INH新点突变。我们的结果证实C1INH(SERPING1)缺陷是一种等位基因高度异质性疾病,几乎每个家族都有其自身的突变。常规分子遗传学分析是在任何临床表现出现之前早期确认临床诊断和识别突变携带者的有效方法。因此,它是预防和适当治疗急性和危及生命水肿的宝贵工具。